Spectral AI showcased its DeepView System at the EBA conference, highlighting advancements in burn care and diagnostic technology.
Quiver AI Summary
Spectral AI, Inc., a Dallas-based company specializing in AI-driven medical diagnostics for wound care, announced its significant participation at the recent European Burns Association (EBA) conference in Berlin, where its DeepView technology was featured in various presentations on burn care innovations. Research from multiple institutions highlighted the effectiveness of Spectral AI's multispectral imaging and predictive analysis for assessing burn wounds. The company's Chairman, Dr. J. Michael DiMaio, expressed pride in the positive reception of DeepView and emphasized ongoing efforts to enhance the technology through physician feedback. Spectral AI aims to revolutionize wound management and improve patient outcomes while reducing healthcare costs.
Potential Positives
- Spectral AI's prominence at the European Burns Association conference highlights its innovative contributions to burn care, enhancing its reputation in the medical community.
- The company's DeepView technology received positive feedback from early adopters, indicating strong potential for adoption and further development in clinical practice.
- The presentations and studies at the conference demonstrate the effectiveness and relevance of Spectral AI's technology, contributing to advancing research in burn wound assessment and treatment.
- Dr. J. Michael DiMaio's expression of pride underscores the company's commitment to improving patient outcomes and its ambition to expand globally in the wound care market.
Potential Negatives
- Heavy reliance on forward-looking statements may create uncertainty for investors regarding the company's future performance and prospects.
- Potential concerns about market adoption, as indicated by the need for ongoing physician feedback and support for the DeepView technology.
- The press release does not provide specific data on clinical outcomes or financial performance, leaving gaps in critical information for stakeholders.
FAQ
What is Spectral AI's focus in medical diagnostics?
Spectral AI specializes in artificial intelligence for faster and more accurate treatment decisions in wound care.
Where was Spectral AI featured recently?
The company played a prominent role at the European Burns Association conference in Berlin, Germany, from September 3rd - 6th, 2025.
What technology does Spectral AI utilize for burn wound assessment?
Spectral AI uses its DeepView System, which incorporates predictive artificial intelligence and multispectral imaging technology.
What feedback has Spectral AI received on its DeepView System?
The DeepView System received positive feedback from physicians and specialists at the EBA conference regarding its efficacy and potential.
How does DeepView System aim to improve patient care?
It aims to provide rapid and accurate assessments of burn wounds, ultimately improving patient outcomes and reducing healthcare costs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDAI Hedge Fund Activity
We have seen 13 institutional investors add shares of $MDAI stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVANTAX PLANNING PARTNERS, INC. removed 231,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $573,713
- VANGUARD GROUP INC added 206,188 shares (+49.5%) to their portfolio in Q2 2025, for an estimated $511,346
- UBS GROUP AG added 99,580 shares (+135.3%) to their portfolio in Q2 2025, for an estimated $246,958
- RENAISSANCE TECHNOLOGIES LLC removed 96,025 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $110,428
- XTX TOPCO LTD added 49,640 shares (+inf%) to their portfolio in Q2 2025, for an estimated $123,107
- DNB ASSET MANAGEMENT AS added 43,024 shares (+inf%) to their portfolio in Q2 2025, for an estimated $106,699
- MARSHALL WACE, LLP added 42,041 shares (+inf%) to their portfolio in Q2 2025, for an estimated $104,261
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDAI Analyst Ratings
Wall Street analysts have issued reports on $MDAI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/02/2025
To track analyst ratings and price targets for $MDAI, check out Quiver Quantitative's $MDAI forecast page.
Full Release
DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the European Burns Association (EBA) conference, held from September 3rd – 6th in Berlin, Germany. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe.
Key Presentations and Posters at EBA:
- Multispectral Imaging and Assessment of Burns Healing Potential: A Prospective Real-World Study to assess the DeepView Snapshot Imaging Platform – Sam Snelling, North Bristol NHS Trust, Bristol, United Kingdom
- The First Reader Study of Burn Wounds with Predictive Artificial Intelligence Analysis – Victoria Miles, Louisiana State University Health and Science Center, New Orleans, US
- Artificial Intelligence-Enhanced Multispectral Imaging for Burn Wound Assessment: Insights from a Multi-Centre UK Trial – Mr. Leslie Poh Hong Tan, Royal Victoria Infirmary, Newcastle, United Kingdom
- Early Experiences of the DeepView System wound imaging technology in a UK regional burn centre – Megan Beese, Queens Elizabeth Hospital, Birmingham, United Kingdom
- Patient Experience of Using Artificial Intelligence-Enhanced Multispectral Imaging to Measure Burn Depth: A Regional Burns Centre Review – Miriam Nyeko-Lacek, Manchester University NHS Foundation Trust, United Kingdom
- Preliminary Experience Using Artificial Intelligence and Multispectral Imaging for Burn Depth Assessment – Nicholas Solanki, Burns Unit Royal Adelaide Hospital, Adelaide, Australia
Mr. Chris Lewis, Consultant Burn and Plastic Surgeon from Royal Victory Infirmary in Newcastle, said “With multiple presentations and posters from my team, colleagues and fellow users of DeepView in the United Kingdom, I was excited to see the results of their research and the interest by the European Burn Specialists. Our institution, as an early adopter, continues to use and see the value of the DeepView technology and we look forward to continuing to develop research and share our findings.”
The European Burns Association Congress is a non-profit forum uniting specialists, researchers, and allied professionals to share knowledge, advance research, and promote best practices in burn prevention and treatment across Europe.
Dr. J. Michael DiMaio, Chairman of the Board of Spectral AI, expressed pride in the Company’s role at the conference: “I am pleased with the DeepView System’s reception and results from our initial placement in the United Kingdom. We continue to seek physician feedback and support to bring this advanced burn wound technology to the worldwide market.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown ® ” with its DeepView System. The DeepView System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com .
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact :
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email:
[email protected]